## **Ahmed Souka**

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3192351/publications.pdf

Version: 2024-02-01

759233 713466 26 439 12 21 h-index citations g-index papers 26 26 26 556 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature. British Journal of Ophthalmology, 2016, 100, 1596-1604.	3.9	62
2	Ageâ€related macular degeneration: using morphological predictors to modify current treatment protocols. Acta Ophthalmologica, 2018, 96, 120-133.	1.1	60
3	Correlation between optical coherence tomography and autofluorescence in acute posterior multifocal placoid pigment epitheliopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2006, 244, 1219-1223.	1.9	54
4	Central retinal vein occlusion: modifying current treatment protocols. Eye, 2016, 30, 505-514.	2.1	33
5	Two-year outcomes of intravitreal ziv-aflibercept. British Journal of Ophthalmology, 2018, 102, 1387-1390.	3.9	26
6	Safety of 5914 intravitreal ziv-aflibercept injections. British Journal of Ophthalmology, 2019, 103, 805-810.	3.9	26
7	Socioeconomic and psychological impact of treatment for unilateral intraocular retinoblastoma. Journal Francais D'Ophtalmologie, 2015, 38, 550-558.	0.4	25
8	Aflibercept in age-related macular degeneration: evaluating its role as a primary therapeutic option. Eye, 2017, 31, 1523-1536.	2.1	23
9	Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab. Ophthalmic Surgery Lasers and Imaging Retina, 2017, 48, 230-236.	0.7	22
10	Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye, 2016, 30, 1531-1541.	2.1	17
11	Long-term safety and efficacy of ziv-aflibercept in retinal diseases. British Journal of Ophthalmology, 2017, 101, 1374-1376.	3.9	15
12	Disparity of microaneurysm count between ultrawide field colour imaging and ultrawide field fluorescein angiography in eyes with diabetic retinopathy. British Journal of Ophthalmology, 2020, 104, 1762-1767.	3.9	14
13	Safety and Efficacy of Ziv-Aflibercept in the Treatment of Refractory Diabetic Macular Edema. Ophthalmic Surgery Lasers and Imaging Retina, 2017, 48, 399-405.	0.7	13
14	Three-month outcomes of ziv-aflibercept in the treatment of diabetic macular oedema. Acta Ophthalmologica, 2016, 94, e669-e669.	1.1	12
15	Comparison between the shortâ€term outcomes of bevacizumab and zivâ€aflibercept in the treatment of primary diabetic macular oedema. Acta Ophthalmologica, 2017, 95, e803-e804.	1.1	9
16	Steroids in Central Retinal Vein Occlusion: Is There a Role in Current Treatment Practice?. Journal of Ophthalmology, 2015, 2015, 1-7.	1.3	7
17	Factors Affecting Predominantly Peripheral Lesion Identification and Grading. Translational Vision Science and Technology, 2021, 10, 6.	2.2	5
18	Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye, 2017, 31, 342-345.	2.1	4

#	Article	IF	CITATIONS
19	Pars Plana Vitrectomy versus Intravitreal Injection of Ranibizumab in the Treatment of Diabetic Macular Edema Associated with Vitreomacular Interface Abnormalities. Journal of Ophthalmology, 2021, 2021, 1-10.	1.3	4
20	Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage. International Journal of Retina and Vitreous, 2020, 6, 2.	1.9	3
21	ARMS2 and HTRA1 gene polymorphisms in association with age-related macular degeneration in an Egyptian cohort. Middle East Journal of Medical Genetics, 2017, 6, 22-28.	0.0	1
22	ASSOCIATION BETWEEN THE VITREOMACULAR INTERFACE AND OPTICAL COHERENCE TOMOGRAPHY CHARACTERISTICS IN WET AGE-RELATED MACULAR DEGENERATION. Retina, 2017, 37, 1738-1745.	1.7	1
23	Cambio a ranibizumab en edema macular diab $ ilde{A}$ ©tico refractario al tratamiento con bevacizumab. Archivos De La Sociedad Espanola De Oftalmologia, 2018, 93, 523-529.	0.2	1
24	Switching to ranibizumab in diabetic macular oedema refractory to bevacizumab treatment. Archivos De La Sociedad Espanola De Oftalmologia, 2018, 93, 523-529.	0.2	1
25	Evaluating peripheral retinal vascularization and rate of recurrence after intravitreal injection of ranibizumab as a primary treatment for retinopathy of prematurity. Journal of the Egyptian Ophthalmological Society, 2020, 113, 125.	0.1	1
26	Response to: â€~Comment on Central retinal vein occlusion: modifying current treatment protocols'. Eye, 2016, 30, 1396-1397.	2.1	0